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An increasing number of manuscripts focus on the in vitro evaluation of established and novel 
antitumor agents in experimental models. Whilst the design of such in vitro assays is inherently 
flexible, some of these studies lack the minimum information necessary to critically evaluate 
their relevance or have been carried out under unsuitable conditions. The use of appropriate and 
robust methods and experimental design has important implications for generating results that 
are reliable, relevant and reproducible. The Pharmacology and Molecular Mechanisms 
(PAMM) group of the European Organization for Research and Treatment of Cancer (EORTC) 
is the largest group of academic scientists working on drug development and bundles decades 
of expertise in this field. This position paper addresses all researchers with an interest in the 
preclinical and cellular pharmacology of antitumor agents and aims at generating basic 
recommendations for the correct use of compounds to be tested for antitumor activity by using 
a range of preclinical cellular models of cancer.  
 







Pharmacology is a complex multidisciplinary science that acts in concert with sister sciences 
including medicinal chemistry, cell biology and physiology, medicine and pharmaceutics 
aiming at identifying useful agents for disease treatment. Over the years the interest of 
researchers in pharmacology, particularly those working at the preclinical level, has increased 
dramatically in several fields including research against cancer. In contrast, in the past few 
decades researchers at several start-up companies, in particular small biotech, and molecular 
biologists neglected pharmacology in drug development and had to learn the hard way the 
importance of insight in drug pharmacology. A key player in the preclinical evaluation of novel 
compounds and established anticancer drugs is the use of cellular models of cancer for 
chemosensitivity studies. This methodology plays a fundamental role in experimental oncology 
studies designed to (i) identify new potential therapeutic agents, (ii) determine the mechanism 
of action (MOA) and (iii) understand pharmacological factors that control the cellular response. 
The design of in vitro tumor cell sensitivity assays is inherently simple and flexible allowing a 
wide range of variables to be tested. However, this simplicity and flexibility is a “double-edged 
sword” and may generate results that cannot always be accurately interpreted or easily 
reproduced in other laboratories. There are many examples of cases where basic errors are 
made in experimental design that can lead to misleading or even erroneous results. 
Furthermore, basic researchers sometimes produce results that have little real pharmacological 
relevance, a consequence of using drug exposure conditions that cannot be achieved in an 
organism [1-3]. In fact, there are examples from the literature showing that different 
mechanisms are activated in response to drug treatment in cell lines depending on the drug 
concentrations [4].  
Applying proper test conditions was a joint collaborative effort of several EORTC groups, the 
Pharmacology and Molecular Mechanisms Groups (PAMM), Screening and Pharmacology 
Group (SGP), New Drug Development group, the Cancer Research Campaign (CRC, now 
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CRUK) and the Development Therapeutics Program (DTP) of the National Cancer Institute 
(NCI) in Bethesda, MD, USA [3]. In this joint program, the so-called NCI-compounds group, a 
workflow was developed to test new compounds coming from the NCI-60 cell line program of 
the NCI, which was based on using proper pharmacology tools to speed up selection of 
potentially active new chemical entities (NCE).The purpose of this article is to provide a series 
of suggestions to ensure that scientific integrity in the conduct of in vitro chemosensitivity 
testing using cellular models is maintained at the highest possible standards. This paper will 
effectively be segregated into two key areas of activity (i) in vitro evaluation of anticancer 
drugs that are in clinical trial or are approved for use in humans and (ii) novel compounds that 
are entering preclinical testing for the first time. In addition, this manuscript will also discuss 
some of the experimental models that are being used to evaluate novel and established 
anticancer agents.  
This article presents the views of members of the EORC-PAMM group. PAMM comprises 
researchers working in the fields of pharmacology, pharmacokinetics-pharmacodynamics, 
pharmacogenetics-pharmacogenomics, molecular mechanisms of anticancer drug effects and 
drug-related molecular pathology (http://www.eortc.org/research-field/pharmacology-
molecular-mechanisms). Our views are designed to present general criteria for preclinical 
studies in which compounds with potential anticancer activity or well-known antitumor agents 
are tested, whilst respecting the fact that the design of in vitro tumor cell sensitivity testing is 
inherently flexible.  
 
Design of in vitro tumor cell sensitivity assay: general principles  
The basic design of in vitro tests for evaluation of tumor cell sensitivity is simple and is 
illustrated in Figure 1. For adherent cell lines, cells are plated into cell culture dishes and 
allowed to ‘adhere and adapt’ to the culture environment for a period of time (typically 
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overnight or 24 hours). Following this time period, cells are treated with the therapeutic agent 
in question for either (i) a defined, short duration of exposure followed by a recovery period to 
allow cells to respond or (ii) continuous drug exposure. Following drug exposure to the test 
agent, cellular response can be assessed by a variety of endpoints and these can be broadly 
divided into (i) clonogenic or (ii) non-clonogenic endpoints [5-7]. Collectively, such tests can 
be referred to as chemosensitivity assays, although originally the prefix “chemo” denoted 
chemical agents that kill microbes or tumor cells. However, in real life, similar assays can be 
employed for multiple tests including chemotherapeutic agents and radiotherapy [8]. It should 
be noted that in this paper “chemotherapy” indicates any chemical entity foreign to the human 
body, including the “classical” cytotoxic compounds (e.g. antimetabolites, nitrogen mustards, 
platinum compounds, tubulin antagonists, anti-tumor antibiotics, etc), as well as novel so-called 
targeted drugs, such as tyrosine kinase inhibitors (TKI), anti-angiogenesis drugs, proteasome 
inhibitors, etc. Each endpoint has its own advantage and disadvantage and the choice of which 
one to use is generally based on individual researcher’s preferences or specific objectives 
(measuring growth inhibition, cell kill, cell survival or effects on cell population growth, for 
example). For suspension cultures, the procedure is effectively the same except for the initial 
conditioning phase which is not mandatory. It is important to recognize that not one single 
assay should be performed as a stand-alone test from which to draw firm conclusions regarding 
in vitro activity against cells. 
Whilst the basic design of in vitro assays is straightforward, the simplicity of this approach 
obscures a multitude of factors that can influence cellular response and therefore affect the 
quality and interpretation of the data obtained. A good understanding of these factors is 
essential to the design of all in vitro chemosensitivity experiments, but is particularly so for 
those addressing specific aspects of tumor biology and drug pharmacology. The following 
sections highlight some of these issues in the context of enhancing good experimental design 
and avoiding poor practice.  
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(i) The use of pharmacologically relevant drug concentrations for established drugs  
Two key pharmacological parameters that determine cellular response are the concentration (C) 
of a drug and the duration of drug exposure (T). For the majority of cytotoxic drugs, cellular 
response is usually proportional to the product of C x T with the exception of drugs that are cell 
cycle phase specific, where cellular response above a certain threshold C is typically 
proportional to T. In this case, extending the duration of drug exposure allows more cells to 
enter the sensitive phase of the cell cycle. For drugs where pharmacokinetics data are available 
(i.e., those that have been approved for use in humans or are in advanced preclinical or early 
clinical trial), it is essential that drug exposure conditions do not exceed those that are 
pharmacologically achievable either in humans. In general terms, therefore, the selection of 
exposure parameters for use in vitro should not exceed the total plasma exposure parameters 
(i.e., area under the curve) achieved in vivo, and the concentrations in preclinical cell-based 
models should aim to be in the same range as the plasma concentrations achievable in vivo 
(Figure 2). This rule is best applicable to haematological malignancies where the target organ is 
the blood itself, whereas less is known about the C x T parameters achieved in solid tumors. 
A series of examples where the effects of using drug exposure parameters that are not 
pharmacologically relevant is given below. Concentrations of anticancer drugs in patients vary 
over several orders of magnitude. The choice of adequate concentrations for in vitro 
experiments is critical, because killing cancer cells can be achieved with almost every 
compound if the concentration is high enough. Results of preclinical experiments using very 
high concentrations can be misleading and often result in false conclusions. For example, as a 
result of using non-pharmacologically relevant concentrations in such experiments, there is 
great confusion about the mechanism of action of anthracyclines in the literature. As pointed 
out by Gerwitz [9] almost 20 years ago, many of the proposed mechanisms for both 
cytotoxicity and cardiotoxicity of anthracyclines are not relevant in patients because of 
exorbitant high drug concentrations used in the preclinical experiments, even exceeding the 
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high peak plasma concentrations achieved during short-term infusion of anthracyclines. 
Nevertheless, mechanisms such as free radical formation for the anti-tumor effects of 
anthracyclines are still mentioned in many textbooks. To complicate the scenario about the 
concentrations of anthracyclines in the tumor, a high and variable tumor to plasma 
concentration ratio of doxorubicin was found in breast cancer patients [10]. Indeed, a high 
tumour to plasma concentration ratio is a result of enrichment of the drug within the tumour 
cells, not in the interstitium, and this is the case for doxorubicin. 
Drug penetration barriers (consisting of influx and efflux pumps) exist for a number of 
anticancer drugs and this - combined with the effect of high interstitial fluid pressure on drug 
penetration into tumors - significantly modifies the C x T parameters experienced by tumor 
cells [11]. The presence of a poor and inefficient vascular supply to tumors leads to the 
establishment of a hypoxic microenvironment where drug delivery is significantly impaired 
[12]. It is technically feasible to measure drug concentrations within a tumor but practically, 
this was rarely done [13], but is getting more common, both for standard cytotoxic and novel 
TKI therapy. In fact, in many current clinical protocols, taking tumor biopsy specimens is 
mandatory and often drug concentrations and other parameters are measured [14]. Basically, 
several methods are available to measure drug concentrations in tissues and include (i) 
quantification in homogenized tumor tissue after surgical excision; (ii) microdialysis by 
inserting a microdialysis needle placed directly into the tumor; (iii) the use of radioactively 
labelled drugs (e.g., short-lived radiolabels, such as 18F); (iv), the use of imaging techniques 
such as NMR and more recently mass-spectrometry based assays. All methods have many 
drawbacks limiting their applicability. Therefore, the plasma concentration has remained the 
golden standard because it has been established for most drugs. Plasma concentrations certainly 
do not give any information on intra-tumoral heterogeneity in drug distribution, and do not give 
any information of drug sequestration, both in the tumor and in normal tissues. For instance, a 
high lysosomal accumulation of sunitinib was found in tumors, due to sequestration in 
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lysosomes [15, 16]. Since lysosomes are less abundant in normal cells, the total cellular 
accumulation is less. Also for the classical anticancer drug 5-fluorouracil (5FU) high 
concentrations (1-10 pmol/mg tumor tissue) have been reported in the tumor, even days after 
administration, in contrast to the rapid plasma half-life with sub nM concentrations after 2 days 
[17]. The latter is due to sequestration in polar metabolites and high-molecular weight 
molecules such as RNA. It should also be recognized that many of the novel drugs (e.g., all 
TKI) are > 95% protein bound [18], or due to their physico-chemical properties are trapped in 
tissues. In animal models, it is usually easier to determine drug concentrations (and their 
retention) in the target tissues (tumor and normal tissues) and get a better indication of the C x 
T. With novel tools such as Positron Emission Tomography (PET), it is currently possible to 
determine the drug concentration in several tissues [19, 20]. In several studies, serum 
concentrations are reported. It should be noted that serum and plasma are often exchanged, 
while serum concentrations are sometimes higher than plasma, since some drugs tend to 
accumulate in platelets, which are lysed during serum preparation. A relative easy alternative 
for drug trapping is the measurement of drug accumulation in red blood cells, in which drugs 
such as the above-mentioned sunitinib and 5FU tend to be retained longer than in plasma.  
Despite this, plasma concentrations after administering therapeutic drug concentrations in 
humans still remain a suitable guide for the selection of conditions for preclinical experiments 
to ensure the most relevant parameters to be used in vitro.  
In the absence of accurate information on the concentration of anticancer drugs in tumors, 
investigators should be encouraged to study putative mechanisms of action of drugs on cultured 
cells at concentrations that impact a therapeutic response (e.g., concentrations that inhibit cell 
growth/survival by 50-90%, IC50 - IC90, Figure 2). The number of cell lines used for these 
studies could vary depending on the molecular hetetogeneity of the tumor type as well as on 
rarity or frequence of the disease. IC50 values are sometimes reported as GI50 (test agent 
concentration which inhibits growth by 50%;  e.g. in data from the NCI-60 panel), while TGI 
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represents total growth inhibition and LC50 (“lethal concentration”, concentration leading to 
death of 50% initially seeded cells – or its equivalent)  response parameters (see for detailed 
definitions: https://dtp.cancer.gov/discovery_development/nci-60/methodology.htlm). By 
including a simple end-point (surrogate for cell count) at the time of test agent addition, one can 
easily ascertain cell growth, test agent concentrations which inhibit net cell growth and 
concentrations which cause net cell death [21, 22]. Thus, one can begin to distinguish cytotoxic 
agents/agent concentrations from cytostatic ones. The response parameter often adopted to 
evaluate cytostasis is TGI (concentration that totally inhibits the net cell growth but do not kill 
cells) – the test agent concentration able to exert total growth inhibition. Very high drug 
concentrations are unfortunately frequently used in the field of anticancer drug research. There 
are numerous examples of the use of cisplatin at concentrations of 10 - 50 M (see [23] for a 
discussion) and 5FU at concentrations > 500 M [24]. However, in these cases the drug 
exposure should be short since for instance 5FU will reach these concentration in plasma after a 
short bolus injection [25], but has a half-life of 10-15 min, while also in the FOLFOX and 
FOLFIRI protocols high concentrations are reached, even for a longer period. Similarly at 
standard doses of 50-100 mg/m2 cisplatin, concentrations may peak between 10-20 μM [26, 27] 
but rapidly decline (half-life < 1 hr). The average IC50 values for both these drugs are 1-10 M 
in the cell lines in the NCI60 panel at 48 h exposure, but for 5FU increase to 200-400 μM and 
for cisplatin up to 200 μM at a short 1-h exposure [28]. This means that in vitro experiments 
with these drugs at high concentration should be limited to a short exposure time. Microtubule 
interacting agents such as paclitaxel are also occasionally used at concentrations 100-fold more 
than their IC50 values [29]. The use of high drug concentrations for a prolonged period is 
convenient since massive apoptosis of cultured tumor cells is generally induced within 24 
hours, a time frame that is ideal for conducting in vitro experiments. Induction of acute 
apoptosis by DNA damaging drugs using high drug concentrations is the subject of a large 
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number of studies. A PubMed search for cisplatin, apoptosis and mechanism generates 1618 
hits (June 2017). The rate of publication of papers examining cisplatin-induced apoptosis has 
increased dramatically during recent years and these studies may represent a questionable use 
of valuable research resources. This problem has been pointed out by different investigators 
over the years [30-32], but the discussion has had limited impact on research directions. At 
even higher drug concentration, DNA damaging drugs have been reported to result in a 
phenomenon referred to as "programmed necrosis" [33]. The relevance of this death mode has 
been disputed [34]. 
The use of high drug concentrations will also accentuate alternative target effects that are 
unlikely to occur at drug concentrations that can be achieved in vivo at oral administration or a 
slow-release form. Cisplatin shows considerable reactivity with proteins due to its 
electrophilicity toward methionine, cysteine and histidine residues; protein adducts may 
therefore constitute the vast majority of cisplatin adducts in exposed cells [35, 36]. Protein 
adducts, usually irreversible, are expected to induce changes in cellular homeostasis only when 
accumulating over a certain threshold. The use of cisplatin concentrations that induce extensive 
formation of protein adducts is likely to lead to effects that are irrelevant to the therapeutically-
relevant mechanism of action of this drug. Although such mechanisms may be of academic 
interest in terms of understanding apoptosis modes, they will not be relevant to understanding 
intrinsic and acquired cisplatin resistance. 
The final-take home message coming from a critical analysis of the literature is that working 
with plasma drug concentration is more biologically reliable than working with high 
concentrations; and this appears to be true for different compounds. 
 
(ii) The use of pharmacologically-relevant drug concentrations for novel compounds 
Whilst the use of pharmacologically-relevant drug exposure parameters is easily defined for 
established drugs or drugs in advanced stages of preclinical/clinical evaluation, this is clearly 
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difficult or even impossible for novel compounds entering the drug discovery process for the 
first time. In this case, the design of the experiments should simply be determination of the 
IC50/GI50 values and this is typically done using continuous drug exposures (48-72 h) in the first 
instance. The initial purpose is to reject compounds that do not have activity. Various selection 
criteria can be applied depending on the drug discovery strategy being pursued. For example, in 
the case of targeted anticancer drug development, drugs should be selected with cells 
expressing the target over those that do not. IC50 values should be comparable or lower than 
that of existing therapeutics (if they exist) or compounds with closely related mechanisms is a 
key decision point. However, it should be considered that mutation of the target may lead to 
resistance to the targeted therapy. 
For compounds following the phenotypic drug discovery route, comparable activity to 
clinically approved reference anticancer drugs (that are chemically related for example) 
together with evidence of selectivity towards the tumor as opposed to non-cancer cell lines is 
appropriate [37, 38], although it has to be acknowledge that most cytotoxics do not discriminate 
between tumor and normal cells. In both cases, the purpose of the in vitro chemosensitivity 
assay is to generate sufficient evidence to select a small number of compounds to progress into 
the next phase of testing and in this case, the use of pharmacologically-relevant drug exposure 
parameters assumes less significance.  
 
(iii) The identification of appropriate exposure times 
It is important to define exposure time of compounds under study. Adequate exposure times  
need to consider both the known mechanism of action of the drug and pharmacokinetic 
parameters. The cytotoxic activity of certain drugs depends mainly on DNA replication, but it 
may not been necessary to treat cells for a period corresponding to one doubling time. This is 
the case for camptothecins and anthracyclines, DNA topoisomerase I and II inhibitors that 
rapidly stabilize the enzyme-DNA cleavable complex, leading to interference with normal DNA 
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functions. The antiproliferative activity of taxanes (e.g., paclitaxel) is due to stabilization of 
microtubuli, resulting in inhibition of the mitotic process.  Prolonged treatment times are 
therefore required to achieve exposure in the critical G2/M phase of the cell cycle. For cisplatin, 
a short term exposure (1 or 2 h) is sufficient to generate DNA mono-adducts that are then 
stabilized or repaired over time. In experiments with targeted agents, a durable inhibition of the 
target is usually needed so that prolonged exposure times are mandatory.  
This additional level of complexity to the problem of exposure time is presented by issues of 
drug uptake and metabolism. For instances, lipophilic drugs are usually rapidly taken up by 
cells and can accumulate intracellularly. For most drugs, especially investigational drugs, it is 
recommended that different exposure times are tested. Additionally, when making comparisons 
between tumor cell lines it is advisable to consider treating cells according to a number of 
doubling times, especially if isogenic pairs of cell lines are used to investigate the role of a 
potential gene or pathway in the mechanism of action of the drug. 
 
(iv) The correct use of solvents to reconstitute pure compounds    
All drugs, whether established or novel unknown compounds have to be dissolved in an 
appropriate solvent and appropriately diluted for use in in vitro chemosensitivity assays. 
Ideally, this should be an aqueous-based buffer but currently many novel compounds are 
insoluble in aqueous buffers. Therefore, dimethylsulphoxide (DMSO) or ethanol are widely 
used. It has been recently pointed out that this simple but fundamental issue in pharmacology 
has been neglected when performing preclinical studies, some of which are reported in high 
impact peer-reviewed journals. One can classify compounds as (i) soluble and solutions can be 
made in aqueous buffers; (ii) insoluble and the drug can be solubilised in either DMSO or 
ethanol; (iii) insoluble and it is recommended that the drug is prepared as a suspension. One 
should refrain from DMSO or ethanol, when the drug is water-soluble. A case in question 
concerns cisplatin that according to a recent paper by Hall et al. [39], has been incorrectly 
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dissolved in DMSO providing results that are misleading and clinically irrelevant. When 
dissolved in DMSO, cisplatin generates adducts that are different from those generated upon 
saline dissolution or when the drug is formulated for clinical use. Thirty years ago, Sundquist et 
al. reported about the species generated when cisplatin was dissolved in DMSO [40]. This 
observation was corroborated later in a publication in which adducts structurally distinct from 
those generated by correctly dissolved cisplatin are described [41]. In principle, cisplatin can be 
dissolved in water, but this generates species with altered cytotoxicity. Early evidence was 
presented about the possible use of “aquated” cisplatin in an attempt to increase the delivery of 
cisplatin to tumors [42]. However, such an approach resulted in increased nephrotoxicity in 
preclinical animal models. Thus, it appears reasonable that some discrepancies in the literature 
regarding platinum drugs might be dependent on the wrong choice of solvent, suggesting the 
need for minimal standard information of drug preparation for all papers in which drugs are 
used.  
An important point in making solutions in pharmacological studies is protein binding, which 
can be reversible and irreversible. Sometimes protein binding is an advantage but more often a 
disadvantage. Also the type of protein is important. Protein binding can be promiscuous or 
specific. An excellent example which clearly affected drug development is the binding of UCN-
01 to alpha-acid glycoprotein, which is not present in culture media, while it is abundant in 
human blood, where UCN-01 is almost completely inactivated. This means that in the early 
phase of drug development, protein binding (human and animal albumin, alpha-acid-
glycoprotein, etc.) should be quantified. On the other hand proteins seem important in the 
intestinal uptake of several of the novel TKI as was demonstrated in the CaCo-2 model [43]. In 
the clinic this is seen with several drugs that show a better bioavailability when taken with food. 
For most TKI protein binding is > 95%, but seems reversible. 
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The use of pharmaceutical compounds versus pure compounds is also an important point that 
should be considered because clinical preparations may contain excipients that may affect cell 
response to the active compound.  
For the clinically available antitumor agents, solvents and solubility have been optimized 
during the course of preclinical and clinical development studies. Drug development efforts 
have highlighted that the effect of the solvent on the activity of the drug under study is crucial, 
and it should be mandatory to provide details about the proper use of drugs in those 
manuscripts where in vitro or in vivo drug activity is tested; this includes a clear description of 
the source of serum. This would be helpful to improve the quality of the published literature as 
well to increase the translatability of the preclinical findings.  
 
(v) Compound stability in vitro 
A frequently underestimated aspect of pharmacology is drug stability throughout the duration 
of the in vitro assay [11, 44], especially those that use continuous drug exposures [12]. The 
stability of a number of cytotoxic drugs in cell culture media has been documented in the 
literature [44], but is frequently ignored with potentially relevant consequences. As an example, 
the selection of novel compounds for further evaluation is often based upon potency but if 
continuous drug exposures are used, the most active in a series of compounds may not 
necessarily be the most potent. In this hypothetical example, consider two compounds, one of 
which is stable in vitro over a prolonged period (compound A) and the other is highly unstable 
in vitro (compound B) with a half-life of less than one hour. Following continuous drug 
exposure, compound A had a lower IC50 value and this would naturally be selected in 
preference to compound B, but this conclusion is potentially misleading as compound B may 
actually be the most potent compound in vitro based upon C x T parameters for the active 
principle. Taking compound stability into consideration early on in the drug development 
process does however introduce logistic and technical challenges, but it is important to 
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acknowledge the potential limitations of interpreting structure activity relationships when 
continuous drug exposures are used. The impact of this problem can be reduced if other 
decision points such as selectivity for cancer versus non-cancer cells are taken into account as 
drug instability caused by chemical breakdown should be the same in both cell types. In 
addition, a simple approach to examine drug stability may be represented by wash out 
experiments. Another example constitutes the chemical instability of 5-aza-2’-deoxycytidine 
(Decitabine). To avoid decreased activity during repetitive freeze-thawing, this compound 
should be frozen in aliquots. Finally, it should also be stressed that breakdown of compounds in 
vitro does not always lead to inactive products (Figure 3). In the case of the alkylating agent 
ThioTEPA for example, it breaks down in vitro to the product TEPA which is just as active as 
the parent compound [45, 46]. 
This example leads us to comment on the in vitro use of pro-drugs. Irinotecan or carboplatin are 
often used in cellular studies and since they are pro-drugs, they are not really suitable for in 
vitro experiments. A good choice would be to employ SN38 instead of irinotecan as the former 
is the active metabolite of irinotecan generated upon the action of carboxylesterases, unless 
investigating mechanisms of resistance to irinotecan, to which reduced levels of 
carboxylesterase can be a contributory factor [47]. Furthermore, cisplatin should be used 
instead of carboplatin because the two compounds form identical adducts [48], but carboplatin 
has a lower rate of activation than cisplatin. With regards to aza-2’-deoxycytidine the intrinsic 
instability of the compound has been addressed by developing stable pro-drugs such as SGI-
110. 
Bio-activation is fundamentally essential for cyclophosphamide to exert its cytotoxic effects. 
Cytochrome P450s, (CYPs) mainly 2B6 and 3A4, oxidize cyclophosphamide to 4-hydroxy-
cyclophosphamide (Figure 3) in the liver and this metabolite can subsequently enter cells and 
decompose to phosphoramide mustard, the ultimate active agent [49]. Therefore, for 
investigating the effects of cyclophosphamide in vitro, the 4-perhydroxy-derivatives must be 
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used, which spontaneously release 4-hydroxy-cyclophosphamide, which is not stable. 
Accordingly, for ifosfamide, 4-perhydroxyifosfamide must be used in cell culture experiments. 
Many publications on cyclophosphamide do not explicitly state if cells were incubated with the 
perhydroxy-derivative or cyclophosphamide itself [50]. 
 
(vi) Tumor microenvironmental factors 
It is widely recognized that cell culture conditions do not mimic the complexity of tumor 
biology and it is questionable as to whether or not this is the real purpose of in vitro testing. The 
inherently flexible design of in vitro assays does allow the influence of tumor biology on 
pharmacology to be explored systematically in a controlled manner. This is particularly true for 
the tumor microenvironment. Together cellular heterogeneity, the physiological changes 
induced by a poor and inefficient blood supply and elevated interstitial fluid pressure can 
modify various aspects of anticancer drug pharmacology [11]. Understanding these factors is 
important in the design of in vitro assays that determine the impact of the tumor 
microenvironment on drug activity and cellular response. Three dimensional models may play a 
role in this context, but it is important to acknowledge that two dimensional models can also 
provide valuable information regarding the impact of specific microenvironmental factors on 
the pharmacology of anticancer drugs. Numerous examples exist in the literature where the 
effects of physiological factors such as hypoxia and acidosis on drugs have been evaluated [51, 
52], but it is again important to stress that physiologically relevant parameters should be used. 
For example, the extracellular pH (pHe) in tumors is generally acidic (pHe typically ranges 
from 6.6 to 7.1) whereas an intracellular pH (pHi) of 7.4 is slightly higher than that in normal 
cells (pHi around 7.2) [53, 54]. This shift in pH gradients in cancer cells has profound 
biological and pharmacological implications [55-58] and it is therefore essential that 
physiologically relevant pH conditions are employed. Studies using more acidic pH values 




Based upon the points raised in the above paragraphs, the following recommendations can be 
made. These are as follows: 
• When data are available concerning the pharmacokinetic parameters achievable in 
humans or rodents, they should be used to guide the selection of concentrations to use in 
the in vitro setting.  
• For novel compounds where pharmacokinetic data is not available, determination of 
IC50, GI50, TGI or LC50 following continuous drug exposure is an appropriate starting 
point.  
• For compounds that are designed to target specific biochemical pathways, the use of cell 
lines where the target is well characterized or has been genetically manipulated is 
appropriate.  
• For compounds where the mechanism of action is not known, comparison of the activity 
of the test compound against a chemically related standard agent (reference compound) 
and/or comparative activity against cancer as opposed to non-cancer cells is desirable. 
Often the NCI-60 cell line panel is a good starting point to find efficacy of drugs with 
similar structure. Data on all drugs tested by the NCI (a few 100,000) are available or 
will shortly become available. The COMPARE program often gives a suitable first 
insight in mechanism of action. 
• Appropriate solvents should be employed to ensure complete solubility and the 
maintenance of the original chemical structure of the compound. Reporting of the 
preparation of compounds for use in vitro should be clear and precise in all publications. 
•  Characterization of physico-chemicals properties will help to define the appropriate 
solvent, but can also predict several important pharmacokinetic properties, such as drug 
penetration, volume of distribution [59]. 
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• Compound stability should be taken into consideration when interpreting 
chemosensitivity data and the use of additional endpoint apart from potency to select 
compounds for further analysis should be considered. Freshly-prepared compound 
stocks and dilutions should be used in assays but where compound supply is limited; the 
preparation of stocks that are batched out and maintained at -20 °C or lower is desirable. 
• Pro-drugs cannot be investigated in the same way as other drugs in experiments with the 
cell lines. Instead the active metabolite itself or compounds spontaneously releasing the 
active metabolite must be used.   
• The endpoints used to measure cellular response can be tailored to the type or number of 
compounds under development; assay and assay conditions (length of drug exposure, 
day of drug addition, correction for absorbance/fluorescence/ cell count at day of drug 
addition) should be included. Just mentioning the commercial name of an assay is not 
sufficient. 
• With regards to testing the effects of specific features of the tumor microenvironment 
(e.g., acidic pHe and reduced oxygenation conditions), it is important to use 
physiologically relevant conditions in two-dimensional culture systems.   
• A number of consideration points to optimize the experimental design are listed in Table 
1.  
The experimental model: general issues 
Over the years there has been an increased tendency to validate the experimental models to 
achieve specific objectives. The most recent example being the use of authenticated cell lines to 
eliminate the possibility of cross contamination of cultures by cells such as the HeLa cell line 
[60]. In contrast, evaluation of the appropriate use of antitumor compounds has been left behind 
and continues to rely on researcher choice and, ultimately, on the judgement of reviewers. Such 
phenomena need to be addressed, as we have long since moved from a time when 
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pharmacological preclinical research was conducted by a relatively small number of scientists 
carrying out preclinical drug development to a scientific context where many academic and 
commercial groups employ multiple pharmacological approaches designed to target biological 
alterations associated with tumor pathogenesis, progression and aggressiveness. 
Thus, given the heterogeneous background of researchers employing drugs in their 
experiments, there are some important issues related to the experimental model that should be 
taken into account. When assaying cell sensitivity to certain drugs, it may be desirable to 
employ proliferating cells unless the experimental design implies that cells should not 
proliferate under the tested conditions. Cell proliferation is necessary for the cells to process the 
damage done to them by drugs, although this may depend on the type of damage. When DNA 
damage is not processed, the cells may turn out to be resistant to the drug (or become tolerant of 
drug-induced lesions) because they do not grow or undergo only a limited number of cell 
divisions during the time of the experiment. This is particularly important both for conventional 
anticancer agents inhibiting DNA-related functions or cell division and for agents targeting 
alterations associated with cell proliferation (e.g., EGF receptor). Low cellular proliferation 
rates and quiescence are however physiologically relevant conditions within hypoxic and 
poorly perfused tumor microenvironments. In the case of drug design it is desirable that new 
compounds target the hypoxic tumor microenvironment and activity against slowly 
proliferating cells [52, 61]. An additional caveat is represented by cells that do not proliferate 
rapidly, such as chronic lymphocytic leukaemia cells. Whilst these cells replicate very slowly, 
they are resistant to apoptosis as a consequence of MCL-1 expression. Agents which down-
regulate MCL-1 expression (e.g., CDK9 inhibitors) impact cell survival and so measurement of 
apoptosis induction becomes the critical assay endpoint [62]. Similarly, normal tissues will 
contain a mix of proliferating undifferentiated cells and non-proliferating differentiated cells 
and therefore studies reporting the response of non-cancer cells need to be carefully interpreted. 
When interpreting observations where the IC50 of novel agents against tumor cells is compared 
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to normal cells, it is important to include standard agents in the study to serve as a “yardstick” 
against which the activity of new agents can be measured. If the new agent performs better than 
the established drug under identical experimental conditions, then there is a reasonable case for 
selecting this compound for further development.  
An experimental model that has attracted major attention in recent years is represented 
by cancer stem cells (CSCs), a cell fraction endowed with self-renewal, differentiating and 
tumor initiating properties being responsible for tumor initiation, invasive growth, metastasis 
and drug resistance [63]. Although CSCs have been identified in several tumor types, the 
precise phenotypic and functional features of CSC have been well defined only in a limited 
number of studies, predominantly leukemia [64, 65], so that the use of preclinical models of 
CSCs, especially in vitro requires major attention (see below).  
 
Testing cell sensitivity to drugs in in vitro assays: a variety of tests 
As mentioned earlier, several end points are widely used to measure the effects of treatments on 
cell lines in vitro and these can be broadly divided into clonogenic and non-clonogenic assays. 
These assays do not only differ in technical nature, but also measure different cell fates. The 
clonogenic assay is a classical method to measure the response of cells following drug exposure 
[4]. The advantage of this assay is its ability to integrate different outcomes (apoptosis, 
necrosis, mitotic catastrophe, senescence) into colony forming ability as a measure of 
replicative potential. Although one is testing the ability of single cells/small cell numbers to 
survive brief exposure and retain proliferative capacity, the obtained data may resemble the 
scenario post tumor resection.  The most commonly used type of endpoint assay however is the 
non-clonogenic assays largely because these can be semi-automated [5]. These assays 
(described in more detail in the next paragraph) are often referred to as determining the 
"cytotoxicity" of drugs which is not entirely correct; the results reflect the difference in cell 
number (or surrogate for cell number) between treated and control cultures due to effects on 
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cell growth/proliferation and/or cell death. Again, each endpoint has its own advantages and 
disadvantages and a detailed discussion of these can be found elsewhere [66].  
With regards to non-clonogenic assays, a variety of assays exist whose suitability can be 
tailored to the specific objective of the study. Commonly used assays include the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] [5], its derivatives (such as the XTT, 
WST), and Alamar Blue assay and the sulforhodamine B (SRB) assay [64] [6].  In the 
MTT/XTT assays, the tetrazolium salts are reduced in the mitochondria of viable cells to 
generate formazan products. Following solubilization of insoluble formazan products in organic 
solvents (MTT assay), the absorbance of the resulting solution can be determined and this is 
proportional to the number of metabolically viable cells within the culture. Similarly, in the 
Alamar Blue assay, resazurin is metabolically reduced to resorufin by viable cells [67]. As these 
assays provide a measure of metabolic activity, the use of these assays to evaluate compounds 
that target cell metabolism should be carefully interpreted and validated using alternative 
endpoints. Furthermore, differences in the pHe of control and treated cultures led to a 
significant underestimation of cell survival in cells treated with interferon using the MTT assay 
[68] and it is strongly recommended that the conditioned culture medium used to culture the 
cells is replaced with fresh medium immediately prior to the addition of MTT. This will apply 
to all assays that depend upon metabolic read outs to measure cellular response. In the SRB 
assay [6], it is possible to measure the dye binding to cellular proteins, again providing an 
indication of cell growth inhibition by treatment. MTT, Alamar blue and SRB assays provide 
surrogate indications/biomarkers of cell number. Many other assays are also available to assess 
cell sensitivity to drugs, e.g. the CellTiterGlo luminescent cell viability assay based on 
quantitation of the ATP present, a further indicator of metabolically active cells. It should be 
recognized that due to their metabolic properties quite a few drugs increase the intracellular 
concentration of ATP. An example is gemcitabine [69]. A simple alternative is staining with 
crystal violet, which is very useful in 96-wells plate assays, as well as to count stained colonies. 
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In the past, the activity of many compounds has been tested by microscopically counting viable 
cells using Trypan blue which is taken-up by dead cells, but excluded by intact membranes of 
viable cells.  As mentioned above, the clonogenic assay [5] is adopted to determine the effects 
of short-term exposure on cell survival and colony formation. However, the clonogenic assay is 
time consuming and less suitable to large scale screenings, but remains very useful to detect 
cell death. Finally and crucially, an irrefutable measure of how a test agent may affect net cell 
numbers can be determined by simply cell counting after fixed exposure periods; cell counting 
allows direct determination of inhibition of cell growth, and when carried out with an automatic 
machine can provide very reproducible results. 
 
Testing cell sensitivity to drugs in in vitro assays: 3D models 
The vast majority of studies of the response to anticancer drugs are carried out using 
subconfluent monolayer cultures, conditions quite distinct from the situation in solid tumors in 
vivo. One strategy to attempt to mimic in vivo conditions is to use multicellular tumor spheroids 
(MCTS) [70, 71], aggregates of tumor cells formed in vitro. An alternative assay employed V-
bottomed plates, in which cells form aggregates as well and resemble 3-dimensional spheroid. 
The advantage of such a system is that it can be evaluated using standard MTT and SRB assays 
[72]. The drug sensitivity properties resemble that of MCTS, as well as drug penetration. The 
sensitivities of MCTS and V-bottom cultures to anticancer drugs is generally lower than the 
sensitivities of monolayer cultures [73, 74]. This is true both for DNA damaging drugs and 
microtubule interacting agents [70, 75]. The major effect of cisplatin exposure of MCTS is 
senescence, whereas apoptosis is only observed in proliferating cell populations in peripheral 
cell layers [75]. The general insensitivity of MCTS to cisplatin and other anticancer drugs is 
likely a consequence of limited drug penetration and the presence of hypoxic, non-proliferating 
cell populations. The MCTS model has been technically improved, allowing spheroids of 
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homogeneous size to form in multiwell plates [70], and the model is in our opinion attractive 
for studies of the response of solid tumor cells to anticancer agents. 
Three-dimensional models have been employed for in vitro assays using CSCs or 
putative CSCs. Indeed, the setting up of reliable drug sensitivity assays is critical because the 
true nature of CSCs is their tumor initiating ability that can be truly assayed only in vivo and 
due to the fact that the best condition would be to use tumor specimens as a source of cells 
maintaining stem-like features. However, isolation of CSCs from clinical specimens is not 
always successful [76]. In principle, once the stemness of a peculiar model has been 
established, drug sensitivity can be assessed by testing drug effects on spheres [77]. In fact, 
CSCs are capable of growing independently of anchorage (i.e. as spheres) in serum-free 
medium added with growth factors. In this context, there are several caveats to consider. For 
example, growth factors activate survival pathways that may influence response to drugs of 
different classes. Therefore, it remains difficult to standardize cell sensitivity assays of CSCs. 
Alternatively, organoid cultures represent an appealing experimental model for testing 
antitumor agents because of the potential to model cancer in vitro, somehow respecting the 
complexity of the disease and recapitulating the three-dimensional tumor organization [78]. The 
use of this appealing technology is still at its infancy, although it appears that it can be 
developed for drug testing by the concomitant employment of different tests to assess cell 
viability or growth. 
 
3D models: Drug penetration  
A major limiting factor in the effectiveness of chemotherapy is poor and inadequate 
extravascular penetration of anticancer drugs [11]. Whilst drug penetration barriers have been 
identified using drugs that are naturally fluorescent or radioactively labelled [11], the 
development of the multicell layer cell culture models have enabled the kinetics of drug 
penetration to be determined using routine analytical techniques [79]. Whilst good penetration 
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of drugs into avascular regions of tumors is desirable in all cases, it is an absolute requirement 
for drugs that are designed to target the hypoxic fraction of tumors [52, 61, 80]. The kinetics of 
drug penetration has been combined with mathematical modelling to generate in silico models 
that can help drug development pathways in terms of selecting and designing compounds that 
can penetrate into such regions of tumors [81, 82].  
 
Testing of drug combinations 
A common goal of preclinical researchers is to discover synergistic interactions between drugs. 
The postulated rationale for the use of combination treatment regimens includes: reduction of 
single agent doses in order to minimize adverse systemic toxicity and spare normal tissues [83, 
84]; target more tumor cells, bearing in mind the heterogeneous nature of malignant disease; 
avoid or delay emergence of acquired drug resistance. However, in combination therapies it is 
often neglected that a reduction of the dose of a drug invariably results in a decreased efficacy, 
while the efficacy of a combination is often not compared to the efficacy of a single drug at its 
maximal tolerated dose (MTD). This means that a combination does not make sense when its 
efficacy is similar or less than that of each single drug at its MTD. Moreover, in a combination 
the drugs may not only enhance the antitumor effect, but also the toxicity. Therefore toxicity of 
the combination should also be compared to that of the single drug at its MTD. 
Nevertheless there are many combinations, which fulfil these criteria and have successfully 
been translated from the cell culture to the mouse model to the patients and clearly improved 
the efficacy compared to the single drugs [85]. Many approaches have been described over the 
years aimed at identification of synergistic interactions, including the simple Bliss 
independence method re-proposed by Kern in 1989 [86], the Loewe isobologram, Webb 
fractional product concept of synergy and the median drug effect methodology developed by 
Chou and Talalay [83, 87]. In this method, a combination index (CI) is calculated at various 
fraction affected (FA) in which a FA of 0 is no effect and a FA of 1 is complete growth 
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inhibition. The Chou and Talalay method is widely used for determination of synergy, 
additivity or antagonism between drugs in combination. However, the method is often used 
incorrectly; e.g. it does not make sense to demonstrate synergism at a total of 25% growth 
inhibition level (FA = 0.25), since that means that the tumor still grows at a 75% rate compared 
to untreated; even an increase to 50% inhibition (FA = 0.5) still means 50% growth of a tumor. 
The normal application of the method is limited to 95% growth inhibition (FA = 0.95) and cell 
kill cannot be included in the formula, since it does not allow negative values nor values of 
FA>1.0. It is recommended that in the application of this method only FA values between 0.5 
and 0.95 are included [84], while an adaptation of the methods also allows evaluation of cell 
kill. 
Unfortunately, there are still papers published where the improved effect of the combination in 
vitro has been assessed in the absence of adequate mathematical analysis, or an incorrect use of 
mathematics. Although discussion of the best method to evaluate drug interaction is out of the 
scope of this manuscript, we would like to highlight the importance of a correct application of 
one of the available methods for assessing synergism in in vitro tests for drug interactions. With 
few exceptions (outlined above), such studies should not rely merely on statistical analyses by 
(for example) the Student’s t (or similar) tests. 
 
Concluding remarks 
The current scenario of pharmacological science implies both pharma-driven efforts and 
academic contribution to innovate drug development and to optimize therapeutic approaches 
toward the path of personalized medicine. The translatability of preclinical research on 
antitumor agents is only in part successful for several reasons, including issues related to 
changes in strategies in academic anticancer drug discovery [3] and experimental models and 
experimental design applied in the preclinical setting [88]. A pertinent example is provided by 
EGFR inhibitors finally discovered to act on the mutant receptor [89]. An improvement in 
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terms of preclinical research translatability may be provided also by the application of more 
stringent criteria and transparency throughout preclinical phases of testing.  
A recent publication authored by Alan Eastman has highlighted the importance of the 
appropriate use of cytotoxicity assays and combination models to improve anticancer drug 
development [90]. The author highlights the high failure rate of anticancer agents considering 
possible drug or experimental model-related reasons. The latter issue is still forefront; also 
taking into account that murine models only in part mirror the complexity of human tumors.  
Additionally, an important point is the development of compounds with a high therapeutic 
index, capable of killing cancer cells while sparing normal ones.  Recently, non-cancer cells 
from different tissues have become available and their use in in vitro testing is helpful, 
especially when cells are derived from tissues normally involved in dose-limiting toxicities.  
There is an urgent need to improve the quality of preclinical results obtained with new 
compounds and with clinically available agents. Researchers in the field of pharmacology 
generally know by virtue of their training about the relevance of solvents, concentrations, use of 
drugs versus pro-drugs, inclusion of pertinent controls and stringent, reproducible assay 
conditions in cellular pharmacology studies. However, researchers in the field of molecular 
biology often lack this background. In this context, attention should be paid (in addition to cell 
culture conditions) to cell behavior and to reagents used for cell culture [91]. In fact, the most 
widely used cell culture supplement (fetal bovine serum) is very complex, its bioactive 
compounds vary between batches and may affect the outcome of cell sensitivity tests. However, 
it should not be difficult for beginners to consider all the possible sources of variability and to 
set up antitumor pharmacology experiments properly, given that all the scientific community 
can access a lot of information about compound solubility, stability and sensitivity assays 
through multiple web-available sources. We hope that the issues raised herein offer the 
opportunity to reflect upon relevant points and act as “pocket” guidelines to motivate good 
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practise in design of pharmacology experiments, and to include in their articles the necessary 
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Table 1. Suggestions in the design of preclinical in vitro testing experiments 
 
 
Choice of the compound concentration 
After testing a wide range of concentrations, am I carrying out the relevant experiments using 
clinically meaningful concentrations? 
 
Choice of the exposure and recovery time 
Do I allow the cells to proliferate long enough to assess the treatment outcome? 
Did I consider cell doubling time? 
Did I match the drug exposure time to the retention of the drug in vivo, a high concentration 
only for a short time?  
 
Choice of solvent 
Is the compound water or fat soluble (lipid and non polar solvents)? 
Is the solvent (e.g. DMSO or ethanol) used at concentrations that are non toxic for the cells?   
Is the dissolved compound stable so that it can be stocked at low temperature (-20°C; -80°C)? 
Does the compound show protein binding; is that reversible? 
 
Choice of the compound 
Is the compound stable? 
Is the compound a pro-drug? 
If I am using a pro-drug in vitro, can I substitute it with the active metabolite?  
 
Choice of cell sensitivity assay 
Does the endpoint of the assay addresses the experimental question correctly? 
Does the method recommend and allow to correct for the number of cells at the time of drug 
addition? 
 
Choice of experimental model  






Legends to figures 
 
Figure 1. Basic experimental design for the conduct of in vitro chemosensitivity assays 
using adherent cell lines. The central bar is a time line and the key steps are placed on this 
time line. The procedures for conducting continuous and timed drug exposures are presented in 
panels A and B respectively. The procedures for suspension cultures are the same with the 
exception of the conditioning period in culture plates which isn’t required. The endpoint here 
refers to non-clonogenic assays as clonogenic assays usually require longer times for colony 
formation to occur. Readings should be performed at the time of drug addition and at the 
endpoint. Intermediate time-points can be very informative since they give insight in the 
dynamics of drug response. With several of the novel assays, that do not require addition of a 
dye, it is possible to do these measurements. 
 
Figure 2. Criteria for selecting drug concentrations and solvent choice for in vitro cell 
sensitivity assays. The two main conditions, i.e. use of established drugs or novel compounds 
are represented, besides a summary of the possible solvents.  
 
Figure 3. Structure of selected drugs, prodrugs and their active metabolites. The alkylating 
agent ThioTEPA breaks down in vitro to TEPA which is equally active as the original 
compound. Cisplatin and carboplatin form identical DNA adducts. SN-38 is the active 
metabolite formed from irinotecan by carboxylesterases. Cyclophosphamide is converted to 4-
hydroxycyclophosphamide by P450. 
 
 
